Cryptococcal fungemia and Mycobacterium haemophilum cellulitis in a patient receiving ruxolitinib: a case report and literature review.
Background: Ruxolitinib is a novel oral Janus kinase inhibitor that is used for treatment of myeloproliferative diseases. It exhibits potent anti-inflammatory and immunosuppressive effects, and may increase the risk of opportunistic infections. Here, we report a rare case of Cryptococcus neoformans...
| Published in: | BMC Infectious Diseases Vol. 21; no. 1; pp. 1 - 8 |
|---|---|
| Main Authors: | , , |
| Format: | case study research Journal Article |
| Published: |
BioMed Central
1/7/2021
|
| Online Access: | View this record in EBSCOhost |